Ongoing clinical trials with high efficacy DMT A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With RelapsingRemitting Multiple Sclerosis (Operetta 2) 2022-2025 233 participants (10-17 years)
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis 2020-2027 Non-randomized Open label Clinical Trial Estimated Enrollment : 36 participants
Annualized relapse rate (primary)
Outcome measures Serum Concentration of Ocrelizumab during treatment according to bodyweight
N of new or enlarging T2- lesions
Levels of CD19+ B-cell Count in Blood
N of T1 Gd lesions
Developmental Milestones
Outcome measures
Incidence and severity of adverse events
Adverse events
